CCR5 deletion mutation and its association with the risk of developing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Haematologica

Volumn 91, Issue 12, 2006, Pages 1628-1634

  Bogunia Kubik, Katarzyna ^a   Duda, Dorota ^b   Suchnicki, Krzysztof ^b   Lange, Andrzej ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b National Bone Marrow Donor Registry   (Poland)

Author keywords

Acute GvHD; CCR5 deletion mutation; HSCT

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CONTROLLED STUDY; DELETION MUTANT; DNA POLYMORPHISM; DONOR SELECTION; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; RISK FACTOR;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE DELETION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MIDDLE AGED; RECEPTORS, CCR5; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33845949485     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft versus host disease. Blood 1992;80:2964-8.
2. Lichtman AH, Krenger W, Ferrara JLM. Cytokine Networks. In: Ferrara JLM, Deeg HJ, Burakoff SJ, eds. Graft versus host disease. New York: M. Dekker, Inc., 1997:179-218.
3. Gouwy M, Struyf S, Proost P, Van Damme J. Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev 2005;16:561-80.
4. Coelho AL, Hogaboam CM, Kunkel SL. Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev 2005;16:553-60.
5. Murai M, Yoneyama H, Harada A, Yi Z, Vestergaard C, Guo B, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 1999;104:49-57.
6. Serody JS, Burkett SE, Panoskaltsis-Mortari A, Ng-Cashin J, McMahon E, Matsushima GK, et al. T-lymphocyte production of macrophage inflammatory protein-1α is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 2000;96:2973-80.
7. New JY, Li B, Koh WP, Ng HK, Tan SY, Yap EH, et al. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant 2002;29:979-86.
8. Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y, Harada A, et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 2003;4:154-60.
9. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, Kirby SL, Luster AD, McKinnon K, et al. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol 2004;173:845-54.
10. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998;187:129-34.
11. Jaksch M, Remberger M, Mattsson J. Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:280-7.
12. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
13. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-73.
14. Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK. The human CC chemokine receptor 5 (CCR5) gene: multiple transcripts with 5-prime-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons. J Biol Chem 1997;272:30662-71.
15. Germana Paterlini M. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys J 2002;3:3012-31
16. Venkatesan S, Petrovic A, Van Ryk DI, Locati M, Weissman D, Murphy PM. Reduced cell surface expression of CCR5 in CCR5Δ32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. J Biol Chem 2002;277:2287-301.
17. Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, et al. Dating the origin of the CCR5-Δ32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 1998;62:1507-15.
18. Libert F, Cochaux P, Beckman G, Samson M, Aksenova M, Cao A, et al. The ΔCCR5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998;7:399-406.
19. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997;16:100-3.
20. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
21. Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-40.
22. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-62.
23. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997;3:23-36.
24. de Roda Husman AM, Koot M, Cornelissen M, Keet IP, Brouwer M, Broersen SM, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997;27:882-90.
25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-8.
26. Smith KM, Crandall KA, Kneissl ML, Navia BA. PCR detection of host and HIV-1 sequences from archival brain tissue. J Neurovirol 2000;6:164-71.
27. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda R, Catano G, et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999;96:12004-9.
28. Welniak LA, Wang Z, Sun K, Kuziel W, Anver MR, Blazar BR, et al. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease. Exp Hematol 2004;32:318-24.
29. Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002;13:754-8.
30. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001;357:1758-61.
31. Fildes JE, Walker AH, Howlett R, Bittar MN, Hutchinson IV, Leonard CT, et al. Donor CCR5Δ32 polymorphism and outcome following cardiac transplantation. Transplant Proc 2005;37:2247-9.
32. Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 5Δ32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl 2004;10:434-9.
33. Schroppel B, Fischereder M, Ashkar R, Lin M, Kramer BK, Mardera B, et al. The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant 2002;2:640-5.
34. Gao W, Faia KL, Csizmadia V, Smiley ST, Soler D, King JA, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001;72:1199-205.
35. + regulatory T cells during acute graft-versus-host disease. Blood 2005;106:3300-7.
36. Tuttle DL, Harrison JK, Anders C, Sleasman JW, Goodenow MM. Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol 1998;72:4962-9
37. Nimura F, Zhang LF, Okuma K, Tanaka R, Sunakawa H, Yamamoto N, et al. Cross-linking cell surface chemokine receptors leads to isolation, activation, and differentiation of monocytes into potent dendritic cells. Exp Biol Med 2006;231:431-43.
38. Bogunia-Kubik K, Jaskula E, Lange A. The presence of CCR5Δ32 deletion mutation associates with a lower incidence of acute GvHD while enhanced CCR55 expression increases the risk of EBV infection. Haematologica 2005;90 Suppl 2:226[abstract 564].
39. Jaskula E, Bogunia-Kubik K, Lange A. CCR5 gene expression may affect the risk of EBV infection: preliminary report. Bone Marrow Transplant 2005;35 Suppl 2:S169[abstract P628].
40. Dickinson AM, Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol 2005;17:517-25.
41. Bogunia-Kubik K, Wysoczanska B, Lange A. Non-HLA gene polymorphisms and the outcome of allogeneic hematopoietic stem cell transplantation. Curr Stem Cell Res Ther 2006;1:239-53.